ASTRAZENECA PLC

AstraZeneca PLC has announced the admission of 11,948 additional ordinary shares to trading on the London Stock Exchange's Main Market. These shares were issued under the company's employee share schemes between October 1 and October 31, 2026, and were admitted under a pre-existing block admission from January 2021. Following this issuance, the total number of AstraZeneca ordinary shares in issue has reached 1,551,065,237, and the new shares are fully fungible with the existing ones.

AstraZeneca PLC has filed a Form 6-K to report its total voting rights as of October 31, 2026. The company stated that it has 1,551,065,237 ordinary shares with voting rights and no shares held in treasury. This total number of voting rights will be used by shareholders to determine if they need to notify the company of any changes to their interest under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca PLC has announced the admission of 9,828 ordinary shares to trading on the Main Market of the London Stock Exchange. These shares were issued under the company's employee share schemes between September 1 and September 30, 2026, and were admitted under a pre-existing block admission. The total number of ordinary shares in issue now stands at 1,551,053,289, and the new shares are fully fungible with existing ones.

AstraZeneca PLC announced that its Chief Financial Officer, Dr. Aradhana Sarin, acquired 73 ordinary shares on September 14, 2026. This acquisition occurred following the vesting of certain dividend equivalent awards that had accrued in relation to her 2021 AstraZeneca Performance Share Plan (AZPSP) award. The underlying award vested on August 17, 2026, but due to processing timelines, dividend equivalents for the first interim dividend of 2026 vested separately. Shares were withheld to cover tax obligations.

AstraZeneca PLC announced that Michel Demaré, Non-Executive Chair of the Board, purchased 2,500 ordinary shares of the company on September 14, 2026. The transaction was executed at a price of GB£121.21 per share. This notification was made in accordance with the EU Market Abuse Regulation.

AstraZeneca PLC announced the appointment of Wan Ling Martello as a Non-Executive Director, effective September 1, 2026. She will also become a member of the Audit Committee. Martello brings significant international experience from her executive leadership roles and board positions at various global businesses, particularly in consumer products and retail industries, with expertise in finance and digital transformation.

AstraZeneca PLC announced the admission of 8,855 further Ordinary Shares of $0.25 each to trading on the London Stock Exchange - Main Market. These shares were issued between July 1, 2026, and July 31, 2026, under the Company's existing block admission for employee share schemes. Following this admission, the total number of Ordinary Shares in issue for AstraZeneca PLC is 1,551,033,389.

AstraZeneca PLC announced its total voting rights as of July 31, 2026. The company reported 1,551,033,389 ordinary shares with voting rights, with no shares held in Treasury. This figure is provided to assist shareholders in complying with the UK Financial Conduct Authority's Disclosure and Transparency Rules regarding notification of their interest in the company.

AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) has received approval in the European Union for the 1st-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. This approval is based on the TROPION-Breast02 Phase III trial, which demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival. Datroway is now the only TROP2-directed antibody drug conjugate approved in the EU with an overall survival benefit for this patient population, offering a new treatment option for an aggressive disease.

AstraZeneca PLC reported strong H1 2026 results with Total Revenue up 6% CER to $30.67 billion and Core EPS up 11% CER to $5.21. Q2 2026 also showed robust growth, with Total Revenue increasing 5% CER to $15.38 billion and Core EPS rising 18% CER to $2.63. The company reconfirmed its FY 2026 guidance for mid-to-high single-digit Total Revenue growth and low double-digit Core EPS growth at constant exchange rates. AstraZeneca also announced two significant licensing agreements, including a $600 million upfront payment for Zegfrovy from Dizal Pharmaceutical and a $200 million upfront payment for TQC3721 from Sino Biopharmaceutical, while acknowledging some pipeline setbacks.